世界中西医结合杂志2025，Vol.20Issue(2)：251-259,9.DOI:10.13935/j.cnki.sjzx.250207
从脾论治法方药联合GLP-1受体激动剂治疗2型糖尿病有效性和安全性的Meta分析
Meta-Analysis of Efficacy and Safety of Spleen-Based Treatment Combined with GLP-1 Receptor Agonists in Treatment of Type 2 Diabetes Mellitus
摘要
Abstract
Objective To compare the efficacy and safety of integrating spleen-based treatment with glucagon-like peptide-1 receptor agonists(GLP-1 RA)and using GLP-1 RA alone in the treatment of type 2 diabetes mellitus(T2DM).Methods A systematic search was conducted in seven databases,including China National Knowledge Infra-structure(CNKI),WanFang Data Resource System,China Biological Medicine(CBM),VIP Information Chinese Science and Technology Journal Database,PubMed,Cochrane Library,and Web of Science,so as to identify randomized controlled trials(RCTs)comparing the spleen-based approach combined with GLP-1 RA(observation group)and GLP-1 RA a-lone(control group)in treating T2DM.Literature screening,data extraction,and quality evaluation were performed.The main outcome measures,including homeostatic model assessment of insulin resistance(HOMA-IR)and homeostasis model assessment of β-cell function(HOMA-β),were calculated and visualized using STATA 17.0 software.Results A total of 17 RCTs involving 1 370 subjects were included.Meta-analysis showed that the observation group has lower HOMA-IR levels[MD=-1.64,95％CI(-2.22,-1.05),P＜0.05]and higher HOMA-β levels compared to the control group[MD=1.88,95％CI(1.36,2.39),P＜0.05].The fasting blood glucose[MD=-1.30,95％CI(-1.79,-0.81),P＜0.05],postprandial blood glucose[MD=-1.05,95％CI(-1.52,-0.59),P＜0.05],glycated hemoglobin[MD=-1.07,95％CI(-1.49,-0.66),P＜0.05],and body mass index[MD=-0.79,95％CI(-1.31,-0.27),P＜0.05]levels were significantly lower in the observation group,while the clinical effective rate was significantly higher[RR=1.20,95％CI(1.08,1.34),P＜0.05].The incidence of gastrointestinal reactions in the observation group was lower than that in the control group(P＜0.05),while no significant differences were observed in the incidence of fatigue,dizzi-ness,or hypoglycemia.Conclusion Integrating spleen-based treatment with GLP-1 RA can significantly improve insu-lin resistance,enhance β-cell function,regulate glucose metabolism,promote weight loss,and reduce the risk of gastroin-testinal reactions.关键词
从脾论治/GLP-1受体激动剂/2型糖尿病/胰岛素抵抗/Meta分析Key words
Spleen-Based Treatment/GLP-1 Receptor Agonists/Type 2 Diabetes Mellitus/Insulin Resistance/Meta-Analysis分类
医药卫生引用本文复制引用
邬倩颖,刘婧,吴恩行,苏冠旬,刘晓玉,杨瑞耕,尚冬梅,王世东..从脾论治法方药联合GLP-1受体激动剂治疗2型糖尿病有效性和安全性的Meta分析[J].世界中西医结合杂志,2025,20(2):251-259,9.基金项目
中央高水平中医医院临床科研业务费资助——北京中医药大学东直门医院领军人才培养项目(DZMG-LCRC0005) （DZMG-LCRC0005）
国家重点研发计划(2018YFC1704402) （2018YFC1704402）
北京市科技计划-G20工程创新研究项目(Z171100001717023) （Z171100001717023）
